Disease Markers / 2017 / Article / Tab 3

Research Article

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma

Table 3

The influence of MMP genotypes on time to progression and overall survival in MPM patients, adjusted for clinical variables.

GeneGenotypeTime to progressionHR (95% CI)Overall survivalHR (95% CI)
Median (25%–75%)Median (25%–75%)

MMP2
rs243865CC8.83 (6.43–15.03)Ref.17.43 (10.60–27.27)Ref.
CT10.17 (6.00–16.33)0.88 (0.63–1.22)0.43717.47 (9.47–31.17)0.96 (0.68–1.36)0.826
TT14.97 (8.20–44.57)0.54 (0.17–1.75)0.30530.00 (22.03–30.00)0.44 (0.11–1.81)0.255
CT + TT10.20 (6.27–16.33)0.85 (0.61–1.18)0.33418.07 (9.63–31.17)0.92 (0.66–1.30)0.653
rs243849CC9.87 (6.13–16.67)Ref.19.10 (9.83–28.13)Ref.
CT8.67 (6.67–14.30)1.30 (0.91–1.86)0.14416.23 (10.80–29.03)1.26 (0.86–1.85)0.227
TT7.33 (3.27–11.80)2.16 (1.02–4.55)0.04317.63 (7.33–36.73)1.18 (0.51–2.72)0.698
CT + TT8.67 (6.60–14.30)1.38 (0.98–1.94)0.06416.63 (10.80–30.27)1.25 (0.87–1.80)0.225
rs7201AA9.27 (6.37–16.93)Ref.16.23 (10.63–28.03)Ref.
AC10.00 (6.73–15.03)0.87 (0.61–1.24)0.44119.30 (10.80–30.00)0.89 (0.62–1.29)0.547
CC8.00 (5.50–12.63)1.15 (0.73–1.80)0.55114.20 (9.23–26.17)1.20 (0.74–1.95)0.467
AC + CC9.80 (6.43–14.57)0.93 (0.67–1.30)0.68418.07 (9.63–29.03)0.96 (0.67–1.36)0.803

MMP9
rs17576AA9.27 (6.13–13.53)Ref.13.57 (9.83–23.90)Ref.
AG10.73 (6.80–18.47)0.84 (0.60–1.17)0.30321.20 (12.17–32.53)0.72 (0.50–1.03)0.070
GG8.50 (6.00–16.67)1.17 (0.69–1.98)0.55816.63 (8.27–26.60)0.96 (0.54–1.68)0.881
AG + GG10.00 (6.67–16.90)0.89 (0.65–1.23)0.47819.30 (11.33–31.17)0.76 (0.54–1.06)0.106
rs2250889CC10.03 (6.73–16.67)Ref.19.10 (11.33–30.00)Ref.
CG6.07 (4.07–7.90)2.32 (1.34–4.03)0.0039.23 (4.53–14.20)2.52 (1.42–4.46)0.002
rs17577GG10.00 (6.60–16.33)Ref.18.07 (10.60–28.30)Ref.
GA8.33 (5.50–14.57)1.20 (0.84–1.72)0.31917.63 (9.47–32.87)0.82 (0.56–1.20)0.311
AA8.83 (8.00–19.43)1.02 (0.32–3.25)0.97713.50 (9.97–25.93)1.58 (0.49–5.04)0.444
GA + AA8.50 (5.53–14.57)1.19 (0.84–1.68)0.33917.63 (9.63–32.53)0.85 (0.59–1.24)0.403
rs20544CC7.53 (5.53–11.53)Ref.13.50 (8.13–21.20)Ref.
CT10.93 (7.37–19.97)0.60 (0.40–0.90)0.01420.67 (11.33–32.53)0.59 (0.39–0.91)0.018
TT9.40 (6.27–14.30)0.67 (0.43–1.03)0.06915.40 (10.80–25.67)0.70 (0.44–1.11)0.132
CT + TT10.13 (6.73–16.20)0.62 (0.43–0.92)0.01619.30 (10.80–31.17)0.63 (0.42–0.95)0.025

MMP14
rs1042703TT9.27 (6.67–16.33)Ref.17.50 (9.97–29.13)Ref.
TC10.17 (6.27–14.53)1.36 (0.94–1.96)0.10019.30 (9.47–29.03)1.25 (0.87–1.81)0.229
CC8.70 (5.13–16.20)2.09 (1.06–4.12)0.03212.70 (7.07–20.60)2.14 (1.12–4.06)0.020
TC + CC10.17 (6.03–14.97)1.44 (1.01–2.03)0.04217.63 (8.30–28.30)1.36 (0.97–1.92)0.076
rs1042704GG9.80 (6.73–14.90)Ref.17.50 (10.80–31.17)Ref.
GA8.30 (5.70–16.20)1.05 (0.74–1.49)0.78017.47 (9.10–24.23)1.40 (0.98–2.00)0.068
AA7.87 (6.00–16.90)0.90 (0.45–1.82)0.77720.27 (13.57–25.93)1.22 (0.59–2.53)0.598
GA + AA8.30 (5.93–16.90)1.03 (0.74–1.42)0.88118.07 (9.63–24.57)1.37 (0.97–1.92)0.072
rs743257CC9.87 (7.07–14.07)Ref.13.50 (9.97–27.27)Ref.
CT9.40 (5.97–19.43)1.08 (0.72–1.64)0.70015.40 (6.80–28.13)0.98 (0.65–1.49)0.931
TT9.70 (6.60–14.53)1.15 (0.75–1.76)0.53520.17 (12.53–31.17)0.87 (0.56–1.36)0.544
CT + TT9.43 (6.07–16.33)1.11 (0.76–1.63)0.58819.30 (9.83–30.27)0.93 (0.63–1.37)0.722

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.